2002年在芬兰收集的肺炎链球菌分离株中大环内酯类耐药的患病率及分子遗传学
Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.
作者信息
Rantala M, Huikko S, Huovinen P, Jalava J
机构信息
Department of Bacteriology and Inflammation, National Public Health Institute, Turku, Finland.
出版信息
Antimicrob Agents Chemother. 2005 Oct;49(10):4180-4. doi: 10.1128/AAC.49.10.4180-4184.2005.
Abstract
The prevalence and mechanisms of macrolide resistance among 1,007 clinical pneumococcal isolates collected in Finland were investigated. Of these, 217 (21.5%) were resistant to erythromycin and 11% to clindamycin. Among the erythromycin-resistant isolates, mef(E) was present in 95 isolates (44%), mef(A) was present in 12 isolates (6%), and erm(B) was present in 90 isolates (41%). A double mechanism, mef(E) and erm(B), was detected in five isolates (2%). Ribosomal mutation was detected in 14 (6%) macrolide-resistant isolates in which no other determinant was found. Based on the telithromycin MICs, two groups of isolates were formed: 83.3% of the isolates belonged to a major group for which the telithromycin MIC range was < or =0.008 to 0.063 microg/ml, and 16.7% belonged to a minor group for which the telithromycin MIC range was 0.125 to 8 microg/ml. All except three isolates in the minor population carried a macrolide resistance gene.
摘要
对在芬兰收集的1007株临床肺炎球菌分离株的大环内酯类耐药性的流行情况及机制进行了研究。其中，217株（21.5%）对红霉素耐药，11%对克林霉素耐药。在红霉素耐药分离株中，95株（44%）存在mef(E)，12株（6%）存在mef(A)，90株（41%）存在erm(B)。在5株分离株（2%）中检测到mef(E)和erm(B)双机制。在14株（6%）大环内酯类耐药分离株中检测到核糖体突变，未发现其他决定因素。根据替利霉素的最低抑菌浓度（MIC），分离株形成两组：83.3%的分离株属于主要组，替利霉素MIC范围为≤0.008至0.063μg/ml，16.7%属于次要组，替利霉素MIC范围为0.125至8μg/ml。次要群体中除3株分离株外均携带大环内酯类耐药基因。
相似文献
1
Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.
Antimicrob Agents Chemother. 2005 Oct;49(10):4180-4. doi: 10.1128/AAC.49.10.4180-4184.2005.
2
Macrolide-resistance mechanisms in Streptococcus pneumoniae isolates from Belgium.
Clin Microbiol Infect. 2005 Apr;11(4):332-4. doi: 10.1111/j.1469-0691.2005.01077.x.
3
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
J Antimicrob Chemother. 2007 Jun;59(6):1171-6. doi: 10.1093/jac/dkm089. Epub 2007 Apr 3.
4
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
J Antimicrob Chemother. 2007 Oct;60(4):733-40. doi: 10.1093/jac/dkm273. Epub 2007 Aug 2.
5
Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
J Antimicrob Chemother. 2002 Sep;50 Suppl S1:39-47. doi: 10.1093/jac/dkf806.
6
Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.
Microb Drug Resist. 2005 Fall;11(3):260-5. doi: 10.1089/mdr.2005.11.260.
7
Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
J Chemother. 2007 Oct;19(5):500-7. doi: 10.1179/joc.2007.19.5.500.
8
Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
J Antimicrob Chemother. 2004 Aug;54 Suppl 1:i17-22. doi: 10.1093/jac/dkh312.
9
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Antimicrob Agents Chemother. 2004 Nov;48(11):4103-12. doi: 10.1128/AAC.48.11.4103-4112.2004.
10
Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.
Antimicrob Agents Chemother. 2002 Feb;46(2):371-7. doi: 10.1128/AAC.46.2.371-377.2002.
引用本文的文献
1
Resistance to Macrolide Antibiotics in Public Health Pathogens.
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a025395. doi: 10.1101/cshperspect.a025395.
2
Functionally cloned pdrM from Streptococcus pneumoniae encodes a Na(+) coupled multidrug efflux pump.
PLoS One. 2013;8(3):e59525. doi: 10.1371/journal.pone.0059525. Epub 2013 Mar 26.
3
Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes.
Int J Antimicrob Agents. 2010 Aug;36(2):124-8. doi: 10.1016/j.ijantimicag.2010.03.024. Epub 2010 May 15.
4
Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.
Antimicrob Agents Chemother. 2009 May;53(5):2066-73. doi: 10.1128/AAC.01464-08. Epub 2009 Mar 9.
5
Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.
Drugs. 2007;67(16):2355-82. doi: 10.2165/00003495-200767160-00005.
6
Molecular epidemiology of telithromycin-resistant pneumococci in Finland.
Antimicrob Agents Chemother. 2007 May;51(5):1885-7. doi: 10.1128/AAC.00187-07. Epub 2007 Feb 26.
7
Pneumolysin polymerase chain reaction for diagnosis of pneumococcal pneumonia and empyema in children.
Eur J Clin Microbiol Infect Dis. 2006 Dec;25(12):783-9. doi: 10.1007/s10096-006-0225-9.
8
Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2006 Nov;50(11):3646-50. doi: 10.1128/AAC.00234-06. Epub 2006 Aug 28.
9
Streptococcus pneumoniae isolates resistant to telithromycin.
Antimicrob Agents Chemother. 2006 May;50(5):1855-8. doi: 10.1128/AAC.50.5.1855-1858.2006.
本文引用的文献
1
Detection and quantification of macrolide resistance mutations at positions 2058 and 2059 of the 23S rRNA gene by pyrosequencing.
Antimicrob Agents Chemother. 2005 Jan;49(1):457-60. doi: 10.1128/AAC.49.1.457-460.2005.
2
Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002.
Antimicrob Agents Chemother. 2004 Sep;48(9):3636-9. doi: 10.1128/AAC.48.9.3636-3639.2004.
3
Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates.
J Clin Microbiol. 2004 Aug;42(8):3570-4. doi: 10.1128/JCM.42.8.3570-3574.2004.
4
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.
Antimicrob Agents Chemother. 2004 Aug;48(8):3169-71. doi: 10.1128/AAC.48.8.3169-3171.2004.
5
Streptococcus agalactiae in a large Portuguese teaching hospital: antimicrobial susceptibility, serotype distribution, and clonal analysis of macrolide-resistant isolates.
Microb Drug Resist. 2004 Spring;10(1):31-6. doi: 10.1089/107662904323047772.
6
Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations.
Diagn Microbiol Infect Dis. 2004 May;49(1):47-52. doi: 10.1016/S0732-8893(03)00130-5.
7
Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes.
Ann Clin Microbiol Antimicrob. 2004 May 6;3:5. doi: 10.1186/1476-0711-3-5.
8
Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.
Antimicrob Agents Chemother. 2004 May;48(5):1882-4. doi: 10.1128/AAC.48.5.1882-1884.2004.
9
Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance.
J Clin Microbiol. 2004 Feb;42(2):764-8. doi: 10.1128/JCM.42.2.764-768.2004.
10
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
J Antimicrob Chemother. 2003 Aug;52(2):229-46. doi: 10.1093/jac/dkg321. Epub 2003 Jul 15.
Zotero 插件